Top segments and regional performance

Last year, the company generated ‪105.29 M‬ EUR, the most of which — ‪107.49 M‬ EUR — came from its top-performing segment, Allogeneic Cellular Medicines Platform, compared to ‪14.82 M‬ EUR the previous year. The greatest contribution came from Australia, United States, Singapore, United Kingdom and Switzerland, which accounted for ‪107.49 M‬ EUR last year, with ‪14.82 M‬ EUR the year before.